← Leaderboards
Benjamin L Wolozin
Boston University Medical Campus
$31,159,035
Attributed
$48,708,919
Total exposure
24
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.9M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,708,919 · 24
By mechanism
R01$22,253,143 · 11
R44$9,431,105 · 3
RF1$8,300,549 · 2
U01$5,370,768 · 2
R21$1,375,349 · 3
R43$1,061,758 · 2
Top collaborators
- Xiaoling Zhang11 shared
- Glenn Larsen10 shared
- Andrew Emili6 shared
- Leonard Petrucelli5 shared
- Peter C Dedon2 shared
- Lindsay A. Farrer2 shared
- Gyungah Jun2 shared
- Hu Li2 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Lawreen H. Connors$2,106,272
- Alpaslan Dedeoglu$7,018,151
- John F. Keaney$9,254,443
- Xiaoling Zhang$4,575,258
- Lindsay A. Farrer$55,579,906
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsProteinsFunctional DisorderNerve DegenerationPathologyBiologyLinkResponseBrainTau ProteinsMutationStressIn VivoAffectMediatingComplexPathway InteractionsExhibitsGenesCellsRna-Binding ProteinsS DiseaseTauopathies
Grant awards (78)
Development of a novel oral brain penetrant therapeutic for ALS disease$1,499,212
R44 · FY2025 · NS
Development of a novel Alzheimer's disease therapeutic targeting tau$998,691
R44 · FY2025 · AG
tRNA Epitranscriptome and Translational Dysfunction in ADRD$848,993
R01 · FY2025 · AG · contact PI
APOE Genotype Mediated Effects on Alzheimer Disease Risk and Mechanisms$785,571
U01 · FY2025 · AG
tRNA modifications regulating mitochondrial function and the mitochondrial proteome in AD/ADRD$781,008
R01 · FY2025 · AG
The role of N6-methyladenosine modified RNA in Alzheimer's disease$780,961
R01 · FY2025 · AG · contact PI
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology$597,829
U01 · FY2025 · AG
Development of a novel Alzheimer's disease therapeutic targeting tau$999,721
R44 · FY2024 · AG
APOE Genotype Mediated Effects on Alzheimer Disease Risk and Mechanisms$810,698
U01 · FY2024 · AG
The role of N6-methyladenosine modified RNA in Alzheimer's disease$783,699
R01 · FY2024 · AG · contact PI
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology$610,029
U01 · FY2024 · AG
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology$408,750
U01 · FY2024 · AG
The role of N6-methyladenosine modified RNA in Alzheimer's disease$806,543
R01 · FY2023 · AG · contact PI
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology$615,144
U01 · FY2023 · AG
Genetic Modifiers of Protein Interaction Networks in Tauopathy$593,467
R01 · FY2023 · AG · contact PI
The role of N6-methyladenosine modified RNA in Alzheimer's disease: Equipment Supplement$55,988
R01 · FY2023 · AG · contact PI
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology$769,284
U01 · FY2022 · AG
Genetic Modifiers of Protein Interaction Networks in Tauopathy$649,483
R01 · FY2022 · AG · contact PI
Targeting tau for the development of novel Alzheimer's disease therapeutics$1,022,579
R44 · FY2021 · AG
Exploring the Pathophysiology of AD and ADRDs with 3D Asteroid Models$916,247
R56 · FY2021 · AG · contact PI
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology$773,463
U01 · FY2021 · AG
Genetic Modifiers of Protein Interaction Networks in Tauopathy$663,204
R01 · FY2021 · AG · contact PI
Targeting tau for the development of novel Alzheimer's disease therapeutics$1,475,961
R44 · FY2020 · AG
Genetic Modifiers of Protein Interaction Networks in Tauopathy$661,315
R01 · FY2020 · AG · contact PI
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteins$410,947
RF1 · FY2020 · AG · contact PI
Systems-level functional proteomics analysis assemblies in Alzheimer's disease and mouse models of tauopathy$3,945,190
RF1 · FY2019 · AG · contact PI
TDP-43 aggregation inhibitors for the treatment of ALS$2,510,981
R44 · FY2019 · NS
Genetic Modifiers of Protein Interaction Networks in Tauopathy$678,318
R01 · FY2019 · AG · contact PI
RNA binding proteins as novel targets in Alzheimer's disease$504,905
R01 · FY2019 · AG · contact PI
Regulation of brain neuroprotection and inflammation by TIA1$247,500
R21 · FY2019 · AG · contact PI
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteins$3,944,412
RF1 · FY2018 · AG · contact PI
TDP-43 aggregation inhibitors for the treatment of ALS$923,960
R44 · FY2018 · NS
RNA binding proteins as novel targets in Alzheimer's disease$503,670
R01 · FY2018 · AG · contact PI
Tau/TIA1 aggregation inhibitors for the treatment of AD$379,465
R43 · FY2018 · AG
The role of acetylation in regulating pathophysiology of tau$263,422
R01 · FY2018 · NS
RNA binding proteins as novel targets in Alzheimer's disease$245,654
R01 · FY2018 · AG · contact PI
Regulation of brain neuroprotection and inflammation by TIA1$206,250
R21 · FY2018 · AG · contact PI
RNA binding proteins as novel targets in Alzheimer's disease$538,004
R01 · FY2017 · AG · contact PI
The role of acetylation in regulating pathophysiology of tau$263,422
R01 · FY2017 · NS
RNA binding proteins as novel targets in Alzheimer's disease$88,476
R01 · FY2017 · AG · contact PI
Stress Granules and the Biology of TDP-43$953,194
R01 · FY2016 · ES · contact PI
RNA binding proteins as novel targets in Alzheimer's disease$516,565
R01 · FY2016 · AG · contact PI
The role of acetylation in regulating pathophysiology of tau$329,278
R01 · FY2016 · NS
TDP-43 aggregation inhibitors for the treatment of ALS$182,737
R43 · FY2016 · NS
Stress Granules and the Biology of TDP-43$969,140
R01 · FY2015 · ES · contact PI
The role of acetylation in regulating pathophysiology of tau$526,845
R01 · FY2015 · NS
TDP-43 aggregation inhibitors for the treatment of ALS$499,556
R43 · FY2015 · NS
RNA binding proteins as novel targets in Alzheimer's disease$495,464
R01 · FY2015 · AG · contact PI
Stress Granules and the Biology of TDP-43$574,627
R01 · FY2014 · ES · contact PI
The role of acetylation in regulating pathophysiology of tau$540,970
R01 · FY2014 · NS
Stress Granules and the Biology of TDP-43$419,775
R01 · FY2014 · ES · contact PI
Stress Granules and the Biology of TDP-43$582,040
R01 · FY2013 · ES · contact PI
LRRK2 and Neurodegeneration$336,167
R01 · FY2013 · NS · contact PI
Stress Granules and the Biology of TDP-43$621,092
R01 · FY2012 · ES · contact PI
LRRK2 and Neurodegeneration$348,359
R01 · FY2012 · NS · contact PI
Identification of compounds that inhibit aggregation and toxicity of TDP-43$255,614
R21 · FY2012 · NS · contact PI
LRRK2 and Neurodegeneration$348,359
R01 · FY2011 · NS · contact PI
The Role of Stress Granules in the Pathophysiology of TDP-43$232,750
R21 · FY2011 · NS · contact PI
Identification of compounds that inhibit aggregation and toxicity of TDP-43$230,110
R21 · FY2011 · NS · contact PI
Interaction Between Genes and the Mitochondria in Parkin$382,714
R01 · FY2010 · ES · contact PI
LRRK2 and Neurodegeneration$351,915
R01 · FY2010 · NS · contact PI
The Role of Stress Granules in the Pathophysiology of TDP-43$203,125
R21 · FY2010 · NS · contact PI
LRRK2 and Neurodegeneration$81,244
R01 · FY2010 · NS · contact PI
Interaction Between Genes and the Mitochondria in Parkin$386,579
R01 · FY2009 · ES · contact PI
LRRK2 and Neurodegeneration$355,469
R01 · FY2009 · NS · contact PI
LRRK2 and Neurodegeneration$34,485
R01 · FY2009 · NS · contact PI
Interaction Between Genes and the Mitochondria in Parkin$386,579
R01 · FY2008 · ES · contact PI
Interaction Between Genes and the Mitochondria in Parkin$394,469
R01 · FY2007 · ES · contact PI
Interaction Between Genes and the Mitochondria in Parkin$406,250
R01 · FY2006 · ES · contact PI
Regulation of APP Processing by Presenilins$268,494
R01 · FY2004 · AG
Ubiquitination/Receptor Signaling--Regulation by Parkin$259,000
R01 · FY2004 · NS
Ubiquitination/Receptor Signaling--Regulation by Parkin$259,000
R01 · FY2003 · NS
Regulation of APP Processing by Presenilins$246,050
R01 · FY2003 · AG
Ubiquitination/Receptor Signaling--Regulation by Parkin$259,000
R01 · FY2002 · NS
Regulation of APP Processing by Presenilins$246,050
R01 · FY2002 · AG
Regulation of APP Processing by Presenilins$337,382
R01 · FY2001 · AG
Ubiquitination/Receptor Signaling--Regulation by Parkin$276,056
R01 · FY2001 · NS
Ubiquitination/Receptor Signaling--Regulation by Parkin$50,000
R01 · FY2001 · NS